LENSAR, the provider of a solution for refractive laser-assisted cataract surgery, has secured $87 million in new capital, including $27 million in equity financing from Aisling Capital, Florida Growth and Florida Opportunity Funds and $60 million in debt financing from PDL BioPharma. The capital will support LENSAR’s long-term growth and continued commercialization throughout North America, Europe, Asia, Latin America and select markets worldwide.
The company has completed a plethora of funding rounds since 2005, raising a total of about $193 million to date. LENSAR reached a $107 million valuation after raising a $4 million funding round in 2011, but saw that valuation drop to $81 million the following year after a $28 million raise. Things picked back up, however, as the company hit its highest valuation to date ($130.5 million) with a $17.4 million raise this past August.
LENSAR’s Augmented Reality technology provides a 3D model of the eye’s anterior anatomy, resulting in customized treatment, while its LENSAR Laser System gives cataract surgeons the power to execute accurate incisions with precision and repeatability.